Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo

Prostate Cancer and Prostatic Diseases volume 6, pages 228–234 (2003)Cite this article

Abstract

In a preclinical model for prostate cancer gene therapy, we have tested lentiviral vectors as a practical possibility for the transfer and long-term expression of the EGFP gene both in vitro and in vivo. The human prostate cancer cell lines DU145 and PC3 were transduced using experimental conditions which permitted analysis of the expression from a single proviral vector per cell. The transduced cells stably expressed the EGFP transgene for 4 months. After injection of the transduced cell populations into Nod-SCID mice a decrease in EGFP was only observed in a minority of cases, while the majority of tumors maintained transgene expression at in vitro levels. In vivo injection of viral vector preparations directly into pre-established subcutaneous or orthotopic tumor masses, obtained by implantation of untransduced PC3 and DU145 cells led to a high transduction efficiency. While the efficiency of direct intratumoral transduction was proportional to the dose of virus injected, the results indicated some technical limitations inherent in these approaches to prostate cancer gene therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Boring CC et al. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7–26.

    Article  CAS  PubMed  Google Scholar 

  2. Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.

    Article  CAS  PubMed  Google Scholar 

  3. Shipley WU et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598–1604.

    Article  CAS  PubMed  Google Scholar 

  4. Huggins C et al. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232–240.

    Article  CAS  PubMed  Google Scholar 

  5. Maitland NJ . Targeting therapeutic gene expression to human prostate cancers. Curr Opin Mol Ther 2000; 2: 389–399.

    CAS  PubMed  Google Scholar 

  6. Steiner MS et al. Gene therapy for prostate cancer: where are we now? J Urol 2000; 164: 1121–1136.

    Article  CAS  PubMed  Google Scholar 

  7. Lu Y et al. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 1999; 6: 64–72.

    Article  CAS  PubMed  Google Scholar 

  8. Young LS et al. The promise and potential hazards of adenovirus gene therapy. Gut 2001; 48: 733–736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yu D et al. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628–635.

    Article  CAS  PubMed  Google Scholar 

  10. Vigna E et al. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308–316.

    Article  CAS  PubMed  Google Scholar 

  11. Bagnis C et al. Viral vectors and gene markers: tools and challenges for scientists working blind on genetic modification of hematopoietic cells. In: Pandalai SG (ed). Recent Research Developments in Virology, Vol. 1. Transworld Research Network, Trivandrum, 1999, pp 217–228; Recent Res Dev Virol 1999; 1: 217–228.

    Google Scholar 

  12. Bastide C et al. A Nod Scid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis 2002; 5: 311–315.

    Article  CAS  PubMed  Google Scholar 

  13. Zufferey R et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873–9880.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Gerolami R et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther 2000; 7: 1286–1292.

    Article  CAS  PubMed  Google Scholar 

  15. Sastry L et al. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Therapy 2002; 9: 1155–1162.

    Article  CAS  PubMed  Google Scholar 

  16. Di Ianni M et al. 5-Azacytidine prevents transgene methylation in vivo. Gene Therapy 1999; 6: 703–707.

    Article  CAS  PubMed  Google Scholar 

  17. Kandel ES et al. Template switching by RNA polymerase II in vivo. Evidence and implications from a retroviral system. Mol Cell Biol 2002; 10: 1495–1502.

    CAS  Google Scholar 

  18. Halvas EK et al. Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity. J Virol 2000; 74: 10349–10358.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mizutani T et al. Maintenance of integrated proviral gene expression requires Brm, a catalytic subunit of SWI/SNF complex. J Biol Chem 2002; 277: 15859–15864.

    Article  CAS  PubMed  Google Scholar 

  20. Hanazono Y et al. Green fluorescent protein retroviral vectors: low liter and high recombination frequency suggest a selective disadvantage. Hum Gene Ther 1997; 8: 1313–1319.

    Article  CAS  PubMed  Google Scholar 

  21. Coleman JE et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221–228.

    Article  CAS  PubMed  Google Scholar 

  22. Horig H et al. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2002; 2: 395–408.

    Article  CAS  PubMed  Google Scholar 

  23. Heiser A et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409–417.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Grant QLK6-CT-2000-00271 from the European Community on behalf of the PIG group (Prostate Cancer: Initiative for Gene Therapy), and by the GVPN (Gene Vector production Network).

Author information

Authors and Affiliations

  1. Institut Paoli-Calmettes, Marseille, France

    C Bastide, N Maroc & J Hassoun

  2. Hopital Salvator, Marseille, France

    F Bladou

  3. University of York, York, UK

    N Maitland

  4. Etablissement Français du Sang Alpes-Méditerranée, Marseille, France

    P Mannoni & C Bagnis

Authors
  1. C Bastide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Maroc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Bladou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Hassoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Maitland
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Mannoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Bagnis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Bagnis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bastide, C., Maroc, N., Bladou, F. et al. Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo. Prostate Cancer Prostatic Dis 6, 228–234 (2003). https://doi.org/10.1038/sj.pcan.4500668

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500668

Keywords

This article is cited by

Search

Advanced search

Quick links